Skip to Content

Join the 'Neuroendocrine Carcinoma' group to help and get support from people like you.

Neuroendocrine Carcinoma News

Related terms: Neuroendocrine Tumor

FDA Approves Lutathera (lutetium Lu 177 dotatate) for Gastroenteropancreatic Neuroendocrine Tumors

Posted 29 Jan 2018 by

January 26, 2018 – The U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointestinal tract called gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This is the first time a radioactive drug, or radiopharmaceutical, has been approved for the treatment of GEP-NETs. Lutathera is ...

Survival Continues to Improve for Most Cancers

Posted 31 Mar 2017 by

FRIDAY, March 31, 2017 – Overall cancer death rates in the United States continue to fall, but racial gaps persist, a new report says. Death rates fell between 2010 and 2014 for 11 of the 16 most common cancers in men and for 13 of the most common types in women, including lung, colon, prostate and breast cancers. However, death rates rose for cancers of the liver, pancreas and brain in men and ...

FDA Approves Netspot (gallium Ga 68 dotatate) Imaging Agent to Detect Rare Neuroendocrine Tumors

Posted 16 Jun 2016 by

June 1, 2016 – The U.S. Food and Drug Administration today approved Netspot, the first kit for the preparation of gallium Ga 68 dotatate injection, a radioactive diagnostic agent for positron emission tomography (PET) imaging. This radioactive probe will help locate tumors in adult and pediatric patients with the rare condition, somatostatin receptor positive neuroendocrine tumors (NETs). NETs ...

FDA Approves Afinitor (everolimus) for Progressive, Nonfunctional Gastrointestinal and Lung Neuroendocrine Tumors (NET)

Posted 29 Feb 2016 by

EAST HANOVER, N.J., Feb. 26, 2016 Novartis today announced that the United States Food and Drug Administration (FDA) approved Afinitor (everolimus) tablets for the treatment of adult patients with progressive, well-differentiated, nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin that are unresectable, locally advanced or metastatic. Afinitor received a priority ...

U.S. Oncologists Decry High Cost of Cancer Drugs

Posted 23 Jul 2015 by

THURSDAY, July 23, 2015 – Soaring costs for cancer drugs are hurting patient care in the United States, a group of top oncologists claim. "High cancer-drug prices are affecting the care of patients with cancer and our health care system," Dr. Ayalew Tefferi, a hematologist at Mayo Clinic in Rochester, Minn., said in a Mayo news release. Tefferi and his colleagues made a number of recommendations ...

Ask a Question

Further Information

Related Condition Support Groups

Carcinoid Tumor, Gastrinoma, Glucagonoma, Insulinoma, Gastroenteropancreatic Neuroendocrine Tumor, Cancer

Related Drug Support Groups

Afinitor, lanreotide, everolimus, Somatuline Depot, Zortress